Patents by Inventor Wenqing Yao

Wenqing Yao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11124511
    Abstract: Disclosed are compounds of Formula (I?), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Grant
    Filed: April 23, 2020
    Date of Patent: September 21, 2021
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Jingwei Li, Wenqing Yao
  • Patent number: 11111247
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting ALK2 activity and/or FGFR activity, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with ALK2 activity and/or FGFR activity, such as cancer.
    Type: Grant
    Filed: September 24, 2019
    Date of Patent: September 7, 2021
    Assignee: Incyte Corporation
    Inventors: Oleg Vechorkin, Minh Nguyen, Chao Qi, Anlai Wang, Liangxing Wu, Wenqing Yao, Peng Zhao
  • Publication number: 20210269434
    Abstract: Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.
    Type: Application
    Filed: January 8, 2021
    Publication date: September 2, 2021
    Inventors: Xiaozhao Wang, Wenyu Zhu, Jeffrey Yang, Alexander Sokolsky, Chunhong He, Zhenwu Li, Chao Qi, Yong Li, Pei Gan, Peter Carlsen, Gia Hoang, Heeoon Han, Chenyin Marshall Law, Fenglei Zhang, Padmaja Polam, Le Zhao, Liangxing Wu, Wenqing Yao
  • Publication number: 20210261555
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.
    Type: Application
    Filed: January 27, 2021
    Publication date: August 26, 2021
    Inventors: Xiaozhao Wang, Heeoon Han, Matthew S. McCammant, Liangxing Wu, Wenqing Yao, Zhiyong Yu, Le Zhao
  • Publication number: 20210230162
    Abstract: Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.
    Type: Application
    Filed: January 20, 2021
    Publication date: July 29, 2021
    Inventors: Le Zhao, Xiaozhao Wang, Wenyu Zhu, Haolin Yin, Liangxing Wu, Wenqing Yao
  • Publication number: 20210230294
    Abstract: Disclosed are combination therapies comprising administration of a CD73 inhibitor and an adenosine A2A or A2B receptor inhibitor. The disclosed combination therapies are useful in the treatment of diseases related to the activity of adenosine receptors and/or CD73 including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases. Anti-CD73 antibodies and A2A/A2B inhibitors are also disclosed.
    Type: Application
    Filed: December 30, 2020
    Publication date: July 29, 2021
    Inventors: Horacio G. Nastri, Shaun M. Stewart, Juan Carlos Almagro, Jing Zhou, Rebecca A. Buonpane, Hui Wang, Yingnan Chen, Xiaozhao Wang, Peter Niels Carlsen, Yong Li, Chao Qi, Liangxing Wu, Wenqing Yao, Wenyu Zhu, Taisheng Huang
  • Publication number: 20210221819
    Abstract: Disclosed are compounds of Formula (I?), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: August 24, 2020
    Publication date: July 22, 2021
    Inventors: Jingwei Li, Liangxing Wu, Wenqing Yao
  • Patent number: 11066404
    Abstract: The present application provides dihydropyrido[2,3-d]pyrimidone inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
    Type: Grant
    Filed: October 10, 2019
    Date of Patent: July 20, 2021
    Assignee: Incyte Corporation
    Inventors: Alexander Sokolsky, Liangxing Wu, Wenqing Yao
  • Publication number: 20210214366
    Abstract: The present disclosure relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR enzyme and are useful in the treatment of FGFR-associated diseases such as cancer.
    Type: Application
    Filed: January 14, 2021
    Publication date: July 15, 2021
    Inventors: Jeremy Roach, Artem Shvartsbart, Michael Witten, Wenqing Yao
  • Publication number: 20210205311
    Abstract: The present application provides methods of treating cancer using a combination of an inhibitor of A2A and/or A2B and an inhibitor of PD-1 and/or PD-L1.
    Type: Application
    Filed: December 30, 2020
    Publication date: July 8, 2021
    Inventors: Hui Wang, Juan Carlos Almagro, Rebecca A. Buonpane, Peter Niels Carlsen, Taisheng Huang, Yong Li, Luping Lin, Horacio G. Nastri, Chao Qi, Shaun M. Stewart, Pramod Unnikrishnan Thekkat, Xiaozhao Wang, Liangxing Wu, Wenqing Yao, Jing Zhou, Wenyu Zhu
  • Patent number: 11053246
    Abstract: The present invention relates to tricyclic compounds, and pharmaceutical compositions of the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.
    Type: Grant
    Filed: April 7, 2020
    Date of Patent: July 6, 2021
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Liangxing Wu, Colin Zhang, Chunhong He, Liang Lu, Wenqing Yao
  • Publication number: 20210171518
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer.
    Type: Application
    Filed: November 16, 2020
    Publication date: June 10, 2021
    Inventors: Joshua Hummel, Oleg Vechorkin, Alexander Sokolsky, Qinda Ye, Kai Liu, Wenqing Yao
  • Publication number: 20210171535
    Abstract: The present disclosure relates to tricyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR enzyme and are useful in the treatment of FGFR-associated diseases such as cancer.
    Type: Application
    Filed: December 3, 2020
    Publication date: June 10, 2021
    Inventors: Matthew S. McCammant, Evan Styduhar, Oleg Vechorkin, Robert Swyka, Wenqing Yao
  • Publication number: 20210163493
    Abstract: The present application provides heteroaryl amide compounds that activate the STING pathway to produce interferons, which are useful in the treatment of various diseases including infectious diseases and cancer.
    Type: Application
    Filed: October 23, 2020
    Publication date: June 3, 2021
    Inventors: Liangxing Wu, Neil Lajkiewicz, Wenqing Yao
  • Patent number: 11014929
    Abstract: Disclosed are compounds of Formula (I): or a pharmaceutically acceptable salt thereof. Also provided are methods of using the compounds of Formula (I) for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer.
    Type: Grant
    Filed: October 3, 2019
    Date of Patent: May 25, 2021
    Assignee: Incyte Corporation
    Inventors: Oleg Vechorkin, Kai Liu, Jun Pan, Alexander Sokolsky, Hai Fen Ye, Qinda Ye, Wenqing Yao, Joshua Hummel
  • Patent number: 11014923
    Abstract: The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR4 enzyme and are useful in the treatment of FGFR4-associated diseases such as cancer.
    Type: Grant
    Filed: July 9, 2020
    Date of Patent: May 25, 2021
    Assignee: Incyte Corporation
    Inventors: Liang Lu, Liangxing Wu, Ding-Quan Qian, Wenqing Yao
  • Patent number: 11008344
    Abstract: The present application provides tricyclic heteroaryl compounds that activate the STING pathway to produce interferons, which are useful in the treatment of various diseases including infectious diseases and cancer.
    Type: Grant
    Filed: July 31, 2019
    Date of Patent: May 18, 2021
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Yingda Ye, Wenqing Yao
  • Publication number: 20210139485
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts or stereoisomers thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.
    Type: Application
    Filed: October 22, 2020
    Publication date: May 13, 2021
    Inventors: Xiaozhao Wang, Pei Gan, Heeoon Han, Taisheng Huang, Matthew S. McCammant, Chao Qi, Ding-Quan Qian, Liangxing Wu, Wenqing Yao, Zhiyong Yu, Fenglei Zhang
  • Publication number: 20210115068
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: December 29, 2020
    Publication date: April 22, 2021
    Inventors: Liangxing Wu, Kaijiong Xiao, Wenqing Yao
  • Publication number: 20210115025
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: December 30, 2020
    Publication date: April 22, 2021
    Inventors: Zhiyong Yu, Liangxing Wu, Wenqing Yao